Accessibility Menu
Hikma Pharmaceuticals Plc logo

Hikma Pharmaceuticals Plc(LSE) HIK

Market Cap£3.41BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)+717%
5 Year-40%
1 Year-20%
1 Month+5%
£15.94
-2.21%
-0.36Today
Hikma Pharmaceuticals Plc last closing stock price
MetricPriceDate
Last closeGBX 1,589.002026-07-30
Hikma Pharmaceuticals Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.32%GBX 1,553.002026-07-23
1 month+4.54%GBX 1,520.002026-06-30
3 month+12.86%GBX 1,408.002026-05-01
Year to date+2.52%GBX 1,550.002025-12-31
1 year-20.35%GBX 1,995.002025-07-30
3 year-23.93%GBX 2,089.002023-07-31
5 year-39.95%GBX 2,646.002021-07-30
Since inception+717.19%GBX 1.992005-11-02

Hikma Pharmaceuticals Plc Financials at a Glance

Market Cap

£3.41BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.48B

Net Income (TTM)

$761.79M

EPS (TTM)

£1.38

P/E Ratio

11.77

Dividend

£0.62

Beta (Volatility)

0.06 (Low)

Price

£15.94

Volume

573,678

Open

£16.25

Previous Close

£15.94

Daily Range

£15.88 - £16.26

52-Week Range

£11.87 - £20.02

Estimated Earnings Date

Aug 6, 2026

HIK News

Why Unilife, Gray Television, and Clovis Oncology Are Today's 3 Best Stocks

Sean WilliamsNov 20, 2013

4 Pharmas With Promising Futures

Brian RichardsJul 31, 2012

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals PLC is a global pharmaceutical company engaged in the development, manufacturing, and distribution of a diverse range of generic, branded, and licensed medications. The company operates through three main segments: Injectables, Generics, and Branded, providing a wide array of medicinal solutions across various dosage forms.

Products and Services
  • Injectables: Focus on generic injectable medications for hospital use
  • Generics: Supply of oral and non-injectable generic pharmaceuticals
  • Branded: Proprietary and in-licensed products for retail and hospital clients
Growth Outlook
  • Revenue growth of 2% in Q4 2025 compared to Q3 2025
  • Strong demand for injectables driving market expansion
  • Strategic investments in R&D to enhance product pipeline
Financial Highlights
  • Q4 2025 net income of $164.8 million, reflecting a 10% increase
  • TTM revenue of $6.7 billion, showcasing consistent performance
  • Dividend yield of 3.97%, indicating strong shareholder returns
Hikma Pharmaceuticals PLC has established a robust presence in the pharmaceutical industry, with a focus on addressing a wide range of medical conditions. The company's strategic segmentation allows for targeted growth in key markets, particularly in injectables, which are experiencing heightened demand. Recent financial performance indicates a positive trajectory, with notable revenue growth and a solid net income increase in the latest quarter. The commitment to research and development further positions Hikma for future success, making it an intriguing option for potential investors interested in the healthcare sector.
AI Generated • Jul 20, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

9,400

CEO

Riad Mishlawi

Website

www.hikma.com

Headquarters

London, GL W1H 6AZ, GB

HIK Financials

Key Financial Metrics (TTM)

Gross Margin

41.35%

Operating Margin

16.81%

Net Income Margin

12.00%

Return on Equity

15.83%

Return on Capital

13.81%

Return on Assets

7.10%

Earnings Yield

8.50%

Dividend Yield

3.80%

Payout Ratio

45.16%

Stock Overview

Market Cap

£3.41BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

209.43M

Volume

573.68K

Avg. Volume

922.20K

Financials (TTM)

Gross Profit

$2.80B

Operating Income

$1.18B

EBITDA

$1.46B

Operating Cash Flow

$953.94M

Capital Expenditure

-$360.38M

Free Cash Flow

$593.56M

Cash & ST Invst.

$354.13M

Total Debt

$1.60B

Hikma Pharmaceuticals Plc Performance Analysis

Hikma Pharmaceuticals Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,043,384,07210.1%
20232023-12-31USD 2,312,856,07113.2%
20242024-12-31USD 2,447,151,2555.8%
20252025-12-31USD 2,541,182,7523.8%
Hikma Pharmaceuticals Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-308.4%
Q42024-12-31-0.7%
Q22025-06-306.4%
Q42025-12-312.5%
Hikma Pharmaceuticals Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.68-48.4%
20232023-12-31USD 0.691.3%
20242024-12-31USD 1.2682.9%
20252025-12-31USD 1.379.0%
Hikma Pharmaceuticals Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30288.5%
Q42024-12-31-40.6%
Q22025-06-3017733.3%
Q42025-12-31-99.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$1.70B

+17.3%

Gross Profit

$673.22M

-2.7%

Gross Margin

39.62%

N/A

Market Cap

£3.41BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£363.15K

N/A

Employees

9,400

N/A

Net Income

$164.79M

+179.3%

EBITDA

$410.96M

+19.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$354.13M

+72.7%

Total Debt

$1.60B

+34.7%

Accounts Receivable

$1.08B

+36.8%

Inventory

$1.11B

+24.2%

Long Term Debt

$1.49B

+44.7%

Short Term Debt

$114.00M

-29.2%

Return on Assets

7.10%

N/A

Return on Invested Capital

13.38%

N/A

Free Cash Flow

$101.56M

-66.3%

Operating Cash Flow

$228.94M

-40.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CTEC.LConvaTec Group Plc
£2.29-0.78%
HCM.LHUTCHMED (China) Limited
£1.68-3.46%
AGY.LAllergy Therapeutics plc
£0.05-7.80%
ANCR.LAnimalcare Group plc
£3.35+0.45%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About HIK

What is the current price of Hikma Pharmaceuticals Plc?

Hikma Pharmaceuticals Plc is trading at £15.94 per share.

What is the 52-week range for Hikma Pharmaceuticals Plc?

Over the past 52 weeks, Hikma Pharmaceuticals Plc has traded between £11.87 and £20.02.

How much debt does Hikma Pharmaceuticals Plc have?

As of the most recent reporting period, Hikma Pharmaceuticals Plc reported total debt of $1.19B.

How much cash does Hikma Pharmaceuticals Plc have on hand?

Hikma Pharmaceuticals Plc reported $243.86M in cash and cash equivalents in its most recent financial results.

What is Hikma Pharmaceuticals Plc’s dividend yield?

Hikma Pharmaceuticals Plc currently has a dividend yield of 3.80%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services